Insider Brief
- Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials focused on lung and heart disease, raised $20 million in Series B financing led by Molten Ventures, with participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.
- The capital will fund expansion of Qureight’s 3D deep learning imaging portfolio through a new AI imaging laboratory, extending its models into asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity alongside its existing lung fibrosis work.
- Dr Inga Deakin of Molten Ventures and Anna Salim of Hargreave Hale are joining Qureight’s Board of Directors, as the company, led by co-founder and CEO Dr Muhunthan Thillai, positions itself in a global lung and heart clinical trials market expected to reach $27.5 billion by 2030.
PRESS RELEASE — Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, announced it has raised $20 million in a Series B financing, led by Molten Ventures. Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension also participated in the round. The new capital will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.
The company is building an AI imaging laboratory to house Qureight’s 3D chest imaging Foundation Model, significantly reducing both the data requirement and the time needed to develop new disease models. This will allow Qureight to bring new products to market in new disease areas where there is high demand for advanced imaging analytics to improve clinical trial design: asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. The new disease models will complement Qureight’s existing models in lung fibrosis and expand the Company’s market reach, solidifying its position as a leading imaging company with an end-to-end regulatory compliant disease-agnostic clinical trials platform. To support this growth and meet demand for its imaging CRO services, the funding will also allow Qureight to scale its commercial team, further strengthening its position in the market.
In addition, the funding will enable the development of Qureight’s AI-powered quantitative imaging analytics platform to further improve the speed and design of clinical trials. The Qureight platform includes:
- Global imaging CRO services to improve image handling in clinical trials and support rapid site onboarding and patient inclusion decisions.
- Proprietary AI Lung image biomarkers enable the quantification of compartment specific structural changes that indicate disease progression in a clinical trial.
- Data science products including synthetic control arms that enable comparisons to real trial arms, reducing study costs and duration.
Qureight’s services are already being utilised by biopharma partners, providing real-time insights and precision endpoints to accelerate clinical trials in a number of fibrotic lung diseases.
The global lung and heart clinical trials market is expected to grow to USD $27.5bn by 2030, with a CAGR of 6.9% over the next six years. We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials. We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors. I also welcome Anna Salim of Hargreave Hale to the Board, and thank all of our existing investors who participated in this round. Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world class team, to address a critical demand to accelerate clinical trials. Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market.
— Dr Muhunthan Thillai, MD PhD, Co-founder and CEO
Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision.
— Dr Inga Deakin, PhD, Partner, Molten Ventures
